Related Experiment Video
Updated: Apr 1, 2026
12:34
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
Published on: January 12, 2024
1.4K
Yin-Hua Li-Shi Formula Exerts Anti-Atopic Dermatitis Effects Through Luteolin Targeting AKT/MAPK-IL-6/IL-17 Axis.
Xuemin Wang1, Ning Jia2, Hyewon Joo3
1Department of Traditional Chinese Medicine Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200443, People's Republic of China.
Journal of Inflammation Research
|March 31, 2026
Summary
Yin-Hua Li-Shi Formula (YHLS) effectively treats atopic dermatitis (AD) by targeting the AKT/MAPK pathway. Luteolin, its key component, reduces inflammation and alleviates AD symptoms in mice.
Area of Science:
- Traditional Chinese Medicine (TCM)
- Pharmacology
- Immunology
Background:
- Yin-Hua Li-Shi Formula (YHLS) is a clinically used TCM for atopic dermatitis (AD) in China.
- Its precise therapeutic mechanisms remain largely unelucidated.
Purpose of the Study:
- To elucidate the therapeutic mechanisms of YHLS in treating atopic dermatitis (AD).
- To identify the key bioactive components and molecular targets of YHLS for AD treatment.
Main Methods:
- Chemical profiling using UPLC-MS/MS.
- Network pharmacology and molecular docking to predict targets and binding affinity.
- In vivo validation using a mouse model of MC903-induced AD-like skin lesions.
Main Results:
- Luteolin was identified as the major bioactive component of YHLS targeting AD.
- YHLS demonstrated dose-dependent efficacy in alleviating AD symptoms and reducing inflammatory markers (IgE, IL-6, IL-17, TNF-α).
- YHLS inhibited the phosphorylation of AKT1 and MAPK1, key inflammatory targets.
Conclusions:
- Luteolin is the primary active component mediating YHLS's anti-atopic dermatitis effects.
- YHLS exerts its therapeutic effects by targeting the AKT/MAPK signaling pathway, specifically modulating IL-6 and IL-17 expression.
